Literature DB >> 31427398

Functional Diversity of Myeloid-Derived Suppressor Cells: The Multitasking Hydra of Cancer.

Asha Jayakumar1, Alfred L M Bothwell2.   

Abstract

Myeloid-derived suppressor cells (MDSCs) are immature suppressive cells found in tumors and immunological niches. In this article, we highlight the ability of MDSCs to promote IL-17-producing T cells (Th17) and regulatory T cells in addition to suppressing cytotoxic T cells in different tumor models. These interactions between MDSCs and T cells support tumor growth because IL-17 is tumorigenic in many cancer types and regulatory T cells suppress antitumor T cells. Besides T cells, MDSCs promote regulatory B cells and suppress overall B cell function; however, tumor-evoked regulatory B cells also regulate MDSC function, suggesting cross-regulation between MDSCs and B cells. These multiple functions shed light on how MDSCs dysregulate several arms of host immune response. Moreover, MDSCs promote tumor cell survival and angiogenesis to support tumors. Therefore, the multifunctional feature of MDSCs make them attractive immunotherapeutic targets.
Copyright © 2019 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31427398      PMCID: PMC6703177          DOI: 10.4049/jimmunol.1900500

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Authors:  V Bronte; E Apolloni; A Cabrelle; R Ronca; P Serafini; P Zamboni; N P Restifo; P Zanovello
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

2.  Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro.

Authors:  Susanne Rössner; Constanze Voigtländer; Carsten Wiethe; Jens Hänig; Christian Seifarth; Manfred B Lutz
Journal:  Eur J Immunol       Date:  2005-12       Impact factor: 5.532

3.  Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Authors:  Giovanna Gallina; Luigi Dolcetti; Paolo Serafini; Carmela De Santo; Ilaria Marigo; Mario P Colombo; Giuseppe Basso; Frank Brombacher; Ivan Borrello; Paola Zanovello; Silvio Bicciato; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2006-10       Impact factor: 14.808

4.  Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.

Authors:  Bo Huang; Ping-Ying Pan; Qingsheng Li; Alice I Sato; David E Levy; Jonathan Bromberg; Celia M Divino; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

5.  Cutting edge: STAT6-deficient mice have enhanced tumor immunity to primary and metastatic mammary carcinoma.

Authors:  S Ostrand-Rosenberg; M J Grusby; V K Clements
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

6.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

7.  Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis.

Authors:  Li Yang; Laura M DeBusk; Koari Fukuda; Barbara Fingleton; Brenda Green-Jarvis; Yu Shyr; Lynn M Matrisian; David P Carbone; P Charles Lin
Journal:  Cancer Cell       Date:  2004-10       Impact factor: 31.743

8.  Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  J Leukoc Biol       Date:  2003-08       Impact factor: 4.962

9.  IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.

Authors:  Vincenzo Bronte; Paolo Serafini; Carmela De Santo; Ilaria Marigo; Valeria Tosello; Alessandra Mazzoni; David M Segal; Caroline Staib; Marianne Lowel; Gerd Sutter; Mario P Colombo; Paola Zanovello
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

10.  High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas.

Authors:  S Le Gouvello; S Bastuji-Garin; N Aloulou; H Mansour; M-T Chaumette; F Berrehar; A Seikour; A Charachon; M Karoui; K Leroy; J-P Farcet; I Sobhani
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

View more
  6 in total

Review 1.  The role of myeloid-derived suppressor cells in gastrointestinal cancer.

Authors:  Cheng Cui; Penglin Lan; Li Fu
Journal:  Cancer Commun (Lond)       Date:  2021-03-27

Review 2.  Targeting Myeloid-Derived Suppressor Cells in Cancer Immunotherapy.

Authors:  Yufei Wang; Anna Jia; Yujing Bi; Yuexin Wang; Qiuli Yang; Yejin Cao; Yan Li; Guangwei Liu
Journal:  Cancers (Basel)       Date:  2020-09-15       Impact factor: 6.639

Review 3.  Targeting myeloid villains in the treatment with immune checkpoint inhibitors in gastrointestinal cancer.

Authors:  Chie Kudo-Saito; Narikazu Boku; Hidekazu Hirano; Hirokazu Shoji
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

Review 4.  Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy.

Authors:  Houhui Shi; Kai Li; Yanghong Ni; Xiao Liang; Xia Zhao
Journal:  Front Cell Dev Biol       Date:  2021-07-14

Review 5.  Tumor-Derived Exosomes in Immunosuppression and Immunotherapy.

Authors:  Wioletta Olejarz; Agnieszka Dominiak; Aleksandra Żołnierzak; Grażyna Kubiak-Tomaszewska; Tomasz Lorenc
Journal:  J Immunol Res       Date:  2020-05-22       Impact factor: 4.818

Review 6.  Phenotypes, Functions, and Clinical Relevance of Regulatory B Cells in Cancer.

Authors:  Jin Shang; Haoran Zha; Yufa Sun
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.